The Use of Interferon α in Behçet Disease: Review of the Literature

Seminars in Arthritis and Rheumatism

Volumn 33, Issue 5, 2004, Pages 320-335

  Kötter, Ina ^a   Günaydin, Ilhan ^a   Zierhut, Manfred ^b   Stübiger, Nicole ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Department of Ophthalmology II ^*  (Germany)

Author keywords

Beh e't disease; Interferon alpha treatment

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AUTOANTIBODY; AZATHIOPRINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GAMMA INTERFERON; LIVER ENZYME; PARACETAMOL; PREDNISOLONE; STEROID; THALIDOMIDE;

ALOPECIA; AMENORRHEA; ANOREXIA; ARTHRALGIA; ARTHRITIS; BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FIBROMYALGIA; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPOTENSION; INJECTION PAIN; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSYCHOSIS; REMISSION; REVIEW; SEIZURE; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 11144355802     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2003.09.010     Document Type: Review

References (94)

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341:1284-91.
2. International Study Group for Behçet's Disease: Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
3. Adamantiades B. Sur un cas dìritis a hypopion récidivant. Ann Ocul (Paris) 1931;168:271-8.
4. Behçet H. Über rezidivierende aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschrift 1937;105:1152-7.
5. Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarica R, et al. Mucocutaneous criteria for the diagnosis of Behçet's disease: An analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995;32:968-76.
6. Kim B, LeBoit PE. Histopathologic features of erythema nodosum-like lesions in Behçet disease: A comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol 2000;22:379-90.
7. Kobayashi M, Ito M, Nakagawa A, Matsushita M, Nishikimi N, Sakurai T, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology 2000;36:362-71.
8. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçets disease, the Silk Road and HLA-B51: Historical and geographical perspectives. Tissue Antigens 1999;54:213-20.
9. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(5 suppl 24):S6-12.
10. Direskeneli H. Behçet's disease: Infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001;60: 996-1002.
11. Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome. Infect Immun 1991;59:1434-41.
12. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet 1982;2:1356-61.
13. Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behcet's disease. Clin Exp Immunol 1990;79:28-34.
14. Young C, Lehner T, Barnes CG. CD4 and CD8 cell responses to herpes simplex virus in Behçet's disease. Clin Exp Immunol 1988;73:6-10.
15. Hamzaoui K, Kahan A, Ayed K, Hamza M. Cytotoxic T cells against herpes simplex virus in Behçet's disease. Clin Exp Immunol 1990;81:390-5.
16. Lee S, Bang D, Cho YH, Lee ES, Sohn S. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease. Arch Dermatol Res 1996;288: 179-83.
17. Sohn S, Lee ES, Bang D, Lee S. Behçet's disease-like symptoms induced by the herpes simplex virus in ICR mice. Eur J Dermatol 1998;8:21-3.
18. Sohn S, Lee ES, Lee S. The correlation of MHC haplotype and development of Behçet's disease-like symptoms induced by herpes simplex virus in several inbred mouse strains. J Dermatol Sci 2001;26:173-81.
19. Onder M, Bozkurt M, Gurer MA, Gulekon A, Sezgin P, Imir T. Natural cellular cytotoxicity in Behçet's disease. J Dermatol 1994;21:239-43.
20. Kaneko F, Takahashi Y, Muramatsu R, Adachi K, Miura Y, Nakane A, et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behçet's disease. Br J Dermatol 1985;113:313-8.
21. Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behçet's syndrome. Cochrane Database Syst Rev 2000:CD001084.
22. Meador R, Ehrlich G, Von Feldt JM. Behçet's disease: Immunopathologic and therapeutic aspects. Curr Rheumatol Rep 2002;4:47-54.
23. Ando K, Fujino Y, Hijikata K, Izawa Y, Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol 1999;43:312-7.
24. Shibata K, Takeuchi M, Kikuchi M, Kobayashi I, Maruyama S. A case of Behçet's disease associated with myopathy during cyclosporin treatment. Rinsho Shinkeigaku 1991;31: 847-52.
25. Nomura E, Izumi Y, Yamashita H, Kamei H, Nakamura S, Wakabayashi C, et al. Magnetic resonance imaging of brainstem lesions in a case of neuro-Behçet disease. No To Shinkei 1997;49:273-6.
26. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999;106:586-9.
27. Sakane T, Takeno M. Novel approaches to Behçet's disease. Expert Opin Investig Drugs 2000;9:1993-2005.
28. Isaacs A, Lindenmann J. Virus Interference. Proc R Soc Ser B 1957;47:258-267.
29. Foster GR, Finter NB. Are all type I human interferons equivalent? J Viral Hepat 1998;5:143-52.
30. Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335-6.
31. O'Duffy JD. Critères proposés pour le diagnostic de la maladie de Behçet. Rev Med 1974;36:2371-2379.
32. Mizushima Y. Revised diagnostic criteria for Behçet's disease in 1987. Ryumachi 1988;28:66-70.
33. Stadler R, Bratzke B, Orfanos CE. Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease. Hautarzt 1987;38:453-60.
34. Stadler R, Bratzke B, Baumann I. [Behçet disease and exogenous interferon: A successful treatment study using recombinant alpha-A-IFN]. Hautarzt 1987;38:97-100.
35. Zouboulis CC, Treudler R, Orfanos CE. Adamantiades-Behçet disease: Therapeutic administration of systemic recombinant interferon-alpha-2a. Hautarzt 1993;44:440-5.
36. Durand JM, Kaplanski G, Telle H, Soubeyrand J, Paulo F. Beneficial effects of interferon-alpha 2b in Behçet's disease. Arthritis Rheum 1993;36:1025-6.
37. Durand JM, Soubeyrand J. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 1994;344:333.
38. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MS. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 1994;343:1428.
39. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, et al. Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 1994;21:1098-100.
40. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease. J Am Acad Dermatol 1994;31:617-9.
41. Münke H, Stockmann F, Ramadori G. Possible association between Behçet's syndrome and chronic hepatitis C virus infection. N Engl J Med 1995;332:400-1.
42. Sanchez Roman J, Pulido Aguilera MC, Castillo Palma MJ, Ocana Medina C, Toral Pena A, Lopez-Checa F, et al. The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease). Rev Clin Esp 1996;196:293-8.
43. Azizlerli G, Sarica R, Kose A, Ovul C, Kavala M, Kayabali M, et al. Interferon alfa-2a in the treatment of Behçet's disease. Dermatology 1996;192:239-41.
44. Kötter I, Dürk H, Eckstein A, Zierhut M, Fierlbeck G, Saal JG. Erosive arthritis and posterior uveitis in Behçet's disease: Treatment with interferon alpha and interferon gamma. Clin Exp Rheumatol 1996;14:313-5.
45. Dündar S, Demiroglu H, Ozcebe O, Ozdemir O, Caliskan S, Eldem B. Alpha interferon in Behçet's disease. Hematology Reviews 1996;9:285-90.
46. Zouboulis CC, Orfanos C. Systemic interferon-alfa in the treatment of Adamantiades-Behçet's disease. Rev Rhum Engl Ed 1996;63:559.
47. Massaro AR, Carnevale A, Laudisio A, Tonali P. L'alfa interferone nella malattia di Behçet. Riv Neurobiol 1996;42: 477-80.
48. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G. Interferon alpha for ocular Behçet's disease. Acta Ophthalmol Scand 1997;75:720-2.
49. Grimbacher B, Wenger B, Deibert P, Ness T, Koetter I, Peter HH. Loss of vision and diarrhoea. Lancet 1997;350:1818.
50. Hamza M, ed. The long-term treatment with interferon-alfa2a in Behçet's Disease. Seventh International Conference on Behçet's Disease; 1997; Tunis, Tunisia. Pub Adhoua.
51. Hamza M, ed. Alfa interferon therapy of ocular Behçet's disease-related uveitis: Report of two cases. Seventh International Conference on Behçet's Disease; 1997; Tunis, Tunisia. Pub Adhoua.
52. O'Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, et al. Interferon-alpha treatment of Behçet's disease. J Rheumatol 1998;25:1938-44.
53. Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J Intern Med 1998; 243:367-72.
54. Kötter I, Eckstein AK, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: A pilot study. Br J Ophthalmol 1998;82:488-94.
55. Strohal R, Tschachler E, Breyer S, Uthman A, Simonitsch I, Tratting S, et al. Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: Long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen. Br J Haematol 1998;103: 788-90.
56. Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behçet's disease. Dermatology 2000;201:40-3.
57. Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 2000;84:1437-8.
58. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000;8:293-301.
59. Aoki T, Tanaka T, Akifuji Y, Ueki J, Nakamura I, Nemoto R, et al. Beneficial effects of interferon-alpha in a case with Behçet's disease. Intern Med 2000;39:667-9.
60. Demiroglu H, Özcebe OI, Barista I, Dündar S, Eldem B. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: A randomised trial. Lancet 2000;355:605-9.
61. Bang D, Lee E-S, Lee S, eds. Treatment of severe uveitis of Behçet's syndrome with the combination of interferon alfa 2b and azathioprine: An open study. Eighth and Ninth International Conference on Behçet's Disease; 2000; Reggio Emilia, Italy and Seoul, Korea.
62. Kötter I, Aepinus C, Graepler F, Gartner V, Eckstein AK, Stubiger N, et al. HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha. Ann Rheum Dis 2001;60:83-6.
63. Stübiger N, Kötter I, Deuter C, Zierhut M. Behçet's disease: Uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients. Klin Monatsbl Augenheilkd 2001; 528:768-73.
64. Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behçet disease. J Neuroophthalmol 2001;21:109-11.
65. Kacunaros M, Alicanidu O, Balacucas D, Agapakis D, Palyaleksis K, Karali V, et al. Adamantiadi-Behçet syndrome: Treatment with recombinant leukocytic interferon. Ter Arkh 2001;73:43-5.
66. Alpsoy E, Durusoy C, Yilmaz E, Özgürel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behçet disease: A randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
67. Treatment of ocular Adamantiades-Behçet's disease with interferon-alfa. Tenth International Conference on Behçet's Disease; 2002; Berlin, Germany
68. Efficacy and safety of interferon alfa-2a in intractable Behçet's disease associated uveitis Tenth International Conference on Behçet's Disease; 2002; Berlin, Germany.
69. Horton R. Retraction: interferon alfa-2a in Behçet's disease. Lancet 2000;356:1292.
70. Kötter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Günaydin I, et al. Human recombinant interferon-alpha2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-431.
71. Kötter I, Dürk H, Saal J, Fierlbeck G, Pleyer U, Zierhut M. Therapy of Behçet's disease. Br J Ophthalmol 2003;5:92-7.
72. Durusoy C, Alpsoy E, Yilmaz E. Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A. J Dermatol 1999;26:225-8.
73. Krischer J, Pechere M, Salomon D, Harms M, Chavaz P, Saurat JH. Interferon alfa-2b-induced Meyerson's nevi in a patient with dysplastic nevus syndrome. J Am Acad Dermatol 1999;40:105-6.
74. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-6.
75. Kadayifcilar S, Boyacioglu S, Kart H, Gursoy M, Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 1999;13(Pt 2):241-6.
76. Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou C, Theodosiadis G, et al. Neurovisual impairment: A frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998;27:1421-7.
77. Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994;21:474-7.
78. Budak-Alpdogan T, Demircay Alpdogan O, Direskeneli H, Ergun T, Öztürk A, et al. Skin hyperreactivity of Behçet's patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders. Br J Rheumatol 1998;37:1148-51.
79. Budak-Alpdogan T, Demircay Z, Alpdogan O, Direskeneli H, Ergün T, Bayik M, et al. Behçet's disease in patients with chronic myelogenous leukemia: Possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms. Ann Hematol 1997;74:45-8.
80. Hanley JP, Haydon GH. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leukoc Lymphoma 1998;29:257-68.
81. Lerner DM, Stoudemire A, Rosenstein DL. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 1999;40:428-35.
82. Fukunishi K, Tanaka H, Maruyama J, Takahashi H, Kitagishi H, Ueshima T, et al. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns 1998;24:581-3.
83. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol Today 1996;17:369-372.
84. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-34.
85. Metzger R, Heckl-Östreicher B, Nerl C, Schondelmaier S, Kabelitz D. Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia: Leukemic gamma delta+ T cells are resistant to growth stimulation in vitro but respond to interferon-alpha treatment in vivo. Leukoc Res 1992;16:1087-95.
86. Eguchi K, Kawakami A, Nakashima M, Ida H, Sakito S, Matsuoka N, et al. Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells. Clin Exp Immunol 1992;88:448-54.
87. Koie T, Suzuki K, Shimoyama T, Umeda T, Nakaji S, Sugawara K. Effect of interferon-alpha on production of reactive oxygen species by human neutrophils. Luminescence 2001; 16(1):39-43.
88. Nyhlen K, Linden M, Andersson R, Uppugunduri S. Corticosteroids and interferons inhibit cytokine-induced production of IL-8 by human endothelial cells. Cytokine 2000;12: 355-60.
89. Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Ciccia F, Giardina E. Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease. Clin Exp Rheumatol 2000;18:495-8.
90. Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behçet's disease. Clin Exp Immunol 1988;71: 126-31.
91. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Behçet's disease: Serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000;201:37-9.
92. Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S, et al. Adamantiades-Behçet's disease: Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000;292: 279-84.
93. Evereklioglu C, Er H, Türkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002;11:87-93.
94. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999;118:451-7.